Form 8-K - Current report:
SEC Accession No. 0001437749-23-019502
Filing Date
2023-07-06
Accepted
2023-07-06 16:39:03
Documents
15
Period of Report
2023-06-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230705_8k.htm   iXBRL 8-K 29870
2 EXHIBIT 10.1 ex_541218.htm EX-10.1 11128
3 EXHIBIT 99.1 ex_541332.htm EX-99.1 11995
  Complete submission text file 0001437749-23-019502.txt   207750

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA navb-20230629.xsd EX-101.SCH 3848
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230629_def.xml EX-101.DEF 13379
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230629_lab.xml EX-101.LAB 17543
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230629_pre.xml EX-101.PRE 13356
9 EXTRACTED XBRL INSTANCE DOCUMENT navb20230705_8k_htm.xml XML 4272
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 231074111
SIC: 2835 In Vitro & In Vivo Diagnostic Substances